Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines

“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness of campaigns and analyse traffic. If you continue to use this site we will assume your acceptance.